No Data
No Data
Express News | Ionis Pharmaceuticals Inc: Ion582 Was Safe and Well Tolerated at All Dose Levels
Express News | Ionis Pharmaceuticals Inc: Ion582 Demonstrated Consistent Improvements Across Multiple Functional Domains in Angelman Syndrome Patients
Express News | Ionis Pharmaceuticals Inc: Ionis Plans to Move Ion582 Into Pivotal Trial
Express News | Ionis Announces Positive Topline Results From Phase 1/2a Trial of Ion582 for Angelman Syndrome
Flamingo Therapeutics Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Danvatirsen in Phase 1 for AML/MDS Cancers
-Danvatirsen is now being evaluated in two clinical trials for head and neck and AML/MDS cancers- LEUVEN, Belgium and STRASBOURG, France and PHILADELPHIA, May 16, 2024 /PRNewswire/ -- Flamingo Therap
Ionis to Host 2024 Virtual Annual Meeting of Stockholders
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2024 virtual Annual Meeting of Stockholders followed by a ...